ABOUT QGEL SA
QGel's purpose is to develop and commercialize biotechnology products of therapeutic relevance to improve methods for research and diagnostics in the field of life science. QGel's products enable accelerated scientific exploration, driving to discoveries and developments in life sciences, with particular focus in tissue engineering, stem cell biology, cell and molecular biology and cancer research. QGel's customers are active across the biological spectrum, working to advance fundamental and applied science, therapeutics, regenerative medicine and diagnostics.
QGel SA is a spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL) and the company is based in the Lake Geneva region of Switzerland.
Founded in July 2009, QGel's roots originate in the late 1990s. The technology of QGel™ products was initially developed at the Eidgenössische Technische Hochschule Zürich (ETHZ), at the University of Zürich and at the California Institute of Technology. More recently, applications in the life sciences were developed at Stanford University in Palo Alto.
QGel SA thanks the support received by several groups who encourage innovation and economic development.
Colin Sanctuary, PhD
Chief Executive Officer
Simone Rizzi, PhD
Business and Product Development